Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Liraglutide cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Liraglutide has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

  1. Victoza glycemic-control trials in adults lasted 26 to 52 weeks; the pediatric trial was a 26-week placebo-controlled trial with a 26-week open-label extension (134 participants aged 10 to 17) 1.
  2. LEADER (NCT01179048) randomized 9,340 adults with type 2 diabetes and atherosclerotic cardiovascular disease to Victoza 1.8 mg or placebo for a median duration of 3.5 years 1.
  3. Saxenda was studied in three 56-week randomized placebo-controlled adult trials with titration to 3 mg over 4 weeks (the label also reports discontinuation data from a 160-week trial), and in a 56-week pediatric trial in 251 participants aged 12 to 17 (NCT02918279) 2.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Liraglutide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Liraglutide cycle length?
No cycle is defined. Liraglutide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Liraglutide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Liraglutide dosing reference Full research page

References

  1. VICTOZA (liraglutide) injection: prescribing information (Novo Nordisk), DailyMed set ID 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 FDA label (DailyMed). 2025
  2. SAXENDA (liraglutide) injection: prescribing information (Novo Nordisk), DailyMed set ID 3946d389-0926-4f77-a708-0acb8153b143 FDA label (DailyMed). 2026
  3. Drugs@FDA application records for NDA 022341 (Victoza) and NDA 206321 (Saxenda): original approval dates Drugs@FDA (via openFDA). 2026
  4. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes) N Engl J Med. 2015
  5. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) N Engl J Med. 2016
  6. WADA publishes 2027 Prohibited List (news release, 21 September 2026) WADA. 2026
  7. International Standard Prohibited List 2026 WADA Prohibited List. 2026